SCHEMBL2582566

SCHEMBL2582566

c1ccc2cc(OC3CCC4(CCNCC4)CC3)ccc2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 1/20 0.51
SLC6A4 P31645 7/20 0.48
SLC6A2 P23975 6/20 0.48
KCNH2 Q12809 3/20 0.48
HTR3A P46098 2/20 0.48
HRH1 P35367 2/20 0.46
DDB1 Q16531 1/20 0.45
CRBN Q96SW2 1/20 0.45
SLC6A3 Q01959 4/20 0.43
HTR2A P28223 1/20 0.43
HTR2C P28335 1/20 0.43
HTR7 P34969 1/20 0.43
HTR2B P41595 1/20 0.43
HTR4 Q13639 1/20 0.43
ROCK1 Q13464 5/20 0.43
ROCK2 O75116 1/20 0.43
PRKACA P17612 1/20 0.43
PRKCD Q05655 1/20 0.43
PRKG1 Q13976 1/20 0.43
PKN1 Q16512 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2583032 0.87 IKBKB (0.47) IKBKBSLC6A4SLC6A2HRH1SLC6A3
SCHEMBL11063126 0.84 IKBKB (0.68) IKBKBSLC6A4SLC6A2KCNH2HTR3A
Hydrochloric Acid SCHEMBL7452746 0.83 IKBKB (0.66) IKBKBSLC6A4SLC6A2KCNH2HTR3A
SCHEMBL2583028 0.79 SLC6A4 (0.58) IKBKBSLC6A4SLC6A2HRH1SLC6A3
SCHEMBL2584807 0.79 CYP2A6 (0.47) IKBKBSLC6A4SLC6A2SLC6A3ROCK1
SCHEMBL30477858 0.79 CYP1A2 (0.50) IKBKBSLC6A4SLC6A2KCNH2HTR3A
SCHEMBL16902878 0.79 CYP1A2 (0.50) IKBKBSLC6A4SLC6A2KCNH2HTR3A
SCHEMBL2580009 0.78 MAOA (0.50) ROCK1ROCK2PRKACAPRKCDPRKG1
SCHEMBL2578242 0.77 SLC6A2 (0.44) IKBKBSLC6A4SLC6A2HRH1SLC6A3
SCHEMBL2585974 0.77 SLC6A4 (0.49) SLC6A4SLC6A2KCNH2HRH1SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8049012-B2 3-aza-spiro[5.5]undecane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors NEUROSEARCH A/S (DK) 2011-11-01 US claimed
EP-1899303-B1 NOVEL 3-AZA-SPIRO[5.5]UNDECANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH AS (DK) 2010-09-15 EP claimed
US-20090227613-A1 Novel 3-Aza-Spiro[5.5]Undecane Derivatives and Their Use As Monoamine Neurotransmitter Re-Uptake Inhibitors NEURO SEARCH A/S (DK) 2009-09-10 US claimed
EP-1899303-A1 NOVEL 3-AZA-SPIRO[5.5]UNDECANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NeuroSearch A/S (DK) 2008-03-19 EP claimed
WO-2007000465-A1 NOVEL 3-AZA-SPIRO[5.5]UNDECANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2007-01-04 WO claimed
US-8049012-B2 3-aza-spiro[5.5]undecane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors NEUROSEARCH A/S (DK) 2011-11-01 US disclosed
EP-1899303-B1 NOVEL 3-AZA-SPIRO[5.5]UNDECANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH AS (DK) 2010-09-15 EP disclosed
US-20090227613-A1 Novel 3-Aza-Spiro[5.5]Undecane Derivatives and Their Use As Monoamine Neurotransmitter Re-Uptake Inhibitors NEURO SEARCH A/S (DK) 2009-09-10 US disclosed
EP-1899303-A1 NOVEL 3-AZA-SPIRO[5.5]UNDECANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NeuroSearch A/S (DK) 2008-03-19 EP disclosed
WO-2007000465-A1 NOVEL 3-AZA-SPIRO[5.5]UNDECANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227613-A1 Novel 3-Aza-Spiro[5.5]Undecane Derivatives and Their Use As Monoamine Neurotransmitter Re-Uptake Inhibitors SLC18A2, SLC6A2, SLC6A3 IKBKB 2117/4885SLC6A4 5/4885SLC6A2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.